10

: Pravalip 10. ?  »
|
-

PER OS

Tablets

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) Reduce the risk of myocardial infarcton. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease including prior MI pravastatin is indicated to: 1)Slow the progression of coronary atherosclerosis. 2) Reduce the risk of acute coronary events. b) Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. Pravastatin is indicated to: 1) Reduce the risk of recurrent myocardial infarction. 2)Reduce the risk of undergoing myocardial revascularization procedures. 3) Reduce the risk of stroke or transient ischemic attack (TIA). c) Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb).

132 80 31134 00

Trima Israel Pharmaceutical Products Maabarot Ltd, Israel

03/2010 - 03/2020

.
, .
.
/
Pravastatin sodium 10 MG
Blister aluminium /aluminium 20 x TABLETS 36
Blister aluminium /aluminium 28 x TABLETS 36
Blister aluminium /aluminium 30 x TABLETS 36
Blister aluminium /aluminium 10 x TABLETS 36

*

*

 

.

? !
 »
 
" !
 

. :  »
301
-